Previous Close | 0.7500 |
Open | 0.7500 |
Bid | 0.3500 |
Ask | 2.2500 |
Strike | 95.00 |
Expire Date | 2024-11-15 |
Day's Range | 0.7500 - 0.7500 |
Contract Range | N/A |
Volume | |
Open Interest | 17 |
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).